Australia Diagnostic Imaging Equipment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Australia Diagnostic Imaging Equipment Market Trends and Insights

Rise in Prevalence of Chronic Diseases

Cardiovascular disease and cancer remain leading death drivers, keeping demand for routine multimodal scans high. Indigenous Australians lose nearly 240,000 healthy life-years annually from illness, prompting targeted imaging subsidies in underserved regions.^{[2]Taylor & Francis, “Australian Burden of Disease Study,” tandfonline.com} Vendors now bundle AI triage engines such as GE HealthCare’s CareIntellect to accelerate report delivery for complex oncology pathways. National health data agencies standardize coding to track chronic-disease imaging volumes, supporting predictable equipment upgrades.

Growing Geriatric Population

Australia’s over-65 cohort expands by roughly 3.3% annually, raising incidences of osteoporotic fractures and neurodegenerative disorders that demand age-adapted imaging. Policy frameworks under the National Medical Workforce Strategy address geographic maldistribution that leaves rural elderly communities short of radiology services. Helium-free MRI, such as Siemens MAGNETOM Flow, reduces cryogen dependency while incorporating mood-lighting and noise dampening, addressing comfort concerns for elderly scans. Virtual-care megatrends project remote check-ins with integrated image sharing, shrinking repeat hospital visits for seniors.

Increased Adoption of Advanced Imaging Technologies

Annalise.ai’s CT Brain model, live in 120 Sonic Healthcare sites, improves stroke-lesion detection by 45% and showcases local AI commercialization aptitude. Canon’s Aquilion ONE INSIGHT Edition integrates machine learning for organ-adaptive dose optimization and recently won the 2024 Minnies Award. Handheld ultrasound accelerates point-of-care adoption, with GE’s Vscan Air rated best for workflow and image quality by domain experts. Regulators have introduced fast-track files for software-as-a-medical-device so hospitals can pilot AI within shorter procurement cycles.

Private-Sector Centre Consolidation

Private equity deployed USD 4.5 billion across Australian healthcare in 2022, with diagnostic imaging the headline target. Affinity Equity’s USD 965 million move for Lumus Imaging creates a 150-site network that can standardize AI platforms and negotiate national service contracts. Integral Diagnostics’ merger with Capitol Health positions the enlarged group to deploy Aidoc triage software across both countries, improving workflow automation. Larger chains gain leverage to secure bulk-billing volumes under Medicare reforms that aim for 90% GP billing rates by 2030.

Capital Cost of Advanced Modalities

High capital expenditure requirements for next-generation imaging systems create procurement barriers, particularly for smaller healthcare facilities. High-end 3 T MRI or spectral CT can exceed USD 3 million per unit, a threshold that strains district hospitals. Vendor finance packages and leasing are expanding, yet smaller sites still delay upgrades until depreciation schedules end. Australia’s equipment-lifespan rules grant exemptions for early replacement if efficiency gains are proven, encouraging helium-free swaps. Regulatory compliance costs add complexity, with TGA application audit updates focusing on high-risk devices requiring comprehensive documentation for conformity assessments.

Workforce Shortage of Sonographers

Australia lacks approximately 3,000 qualified sonographers and faces similar challenges, with only one university currently training general sonographers, resulting in a shortage that exceeds 120 full-time equivalent positions. Private practices conduct 70% of ultrasounds but offer limited placements for trainees, creating a bottleneck that affects appointment wait times.^{[3]Australasian Sonographers Association, “Workforce Australia,” sonographers.org} The ASA requests USD 3.466 million over three years to support clinical training placements and regulatory inclusion, aiming to address the 15-year workforce shortage.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Modality: AI Integration Drives CT Expansion

Computed tomography posted the quickest 7.65% CAGR, helping the Australian diagnostic imaging equipment market diversify beyond ultrasound leadership. The CT upswing aligns with bedside units, such as Siemens SOMATOM On-site, that bring neuroimaging directly to intensive care beds. Ultrasound remains indispensable across obstetrics, emergency, and primary care pathways due to its portability and cost advantages. MRI growth benefits from helium-free magnet launches that trim life-cycle costs by up to 30%. X-ray systems have shifted toward flat-panel detectors and streamlined workflow guidance, while fluoroscopy platforms incorporate AI-driven dose optimization. Nuclear imaging’s progress hinges on isotope supply; yet, PET-CT retains its niche strength in oncology staging, backed by rebate increases. Mammography manufacturers are incorporating short scan times and AI lesion triage to meet breast-screening mandates. Together, these upgrades sustain a healthy replacement cycle that underpins modality-level revenue growth within the Australian diagnostic imaging equipment market.

The segment’s technology race fosters multi-vendor AI ecosystems, where algorithms from local firms like Harrison.ai can be deployed across hardware from Canon, GE, or Philips. Vendor neutrality helps private imaging chains standardize analytics fleetwide. As reimbursement now rewards quality metrics over raw throughput, software that reduces repeat scans or accelerates diagnosis holds commercial upside. This environment keeps CT and MRI demand resilient, even when capital budgets are tightened. The Australian diagnostic imaging equipment industry, therefore, witnesses continuous innovation in modalities that align clinical outcomes with cost-containment goals.

By Portability: Mobile Systems Gain Momentum

Fixed rooms still account for 81.44% of revenue, thanks to their comprehensive capabilities; however, mobile and handheld devices are starting to reshape workflows within the Australian diagnostic imaging equipment market. Handheld ultrasound alone recorded more than 2,600 emergency department scans across regional hospitals, achieving a 94% diagnostic utility. Mobile CT and MRI reduce patient transfers, thereby lowering the risk of in-hospital complications. Rural outreach programs leverage truck-mounted magnet units, creating new capital-leasing opportunities for vendors.

The rising adoption of point-of-care services also reflects clinician demand for real-time triage in primary care settings. Artificial intelligence embedded in devices like Philips Lumify automates measurement tasks, which broadens user segments beyond specialist radiologists. Regulatory authorities now provide accelerated routes for low-risk portable devices, shortening the time to market. Collectively, these forces push portability CAGR to 6.88%, reinforcing the decentralization trend that drives incremental equipment sales across the Australian diagnostic imaging equipment market.

By Application: Cardiology Accelerates Growth

Oncology accounted for a 24.63% share in 2025, as scan volumes rose in tandem with higher cancer incidence. Cardiology, however, displays the strongest forecast CAGR of 7.46% due to growing cardiovascular morbidity, new CT-FFR workflows, and AI-based echo automation. GE HealthCare’s Revolution Vibe CT offers unlimited one-beat cardiac imaging, which cuts motion artifacts and reduces beta-blocker pre-medication needs.

Neurology rides on stroke program investments, with AI triage halving door-to-needle time for thrombolysis. Orthopedics benefits from upright CT scans that examine weight-bearing joints, enhancing surgical planning. Gastroenterology utilizes endoscopic ultrasound hybrids for lesion assessment, while women’s health ultrasound incorporates advanced placenta accretion markers. Cross-fertilization between applications ensures steady scanner utilization and secures annuity service contracts, which expand the Australian diagnostic imaging equipment market size.

By End User: Imaging Centers Expand Rapidly

Hospitals held a 69.20% share in 2025, thanks to their dominance in acute care; however, dedicated imaging centers are racing ahead with a 7.31% CAGR as consolidation unlocks scale. Affinity Equity’s Lumus Imaging rollout advances center count, leading to bulk purchasing that lowers per-scan costs. Sonic Healthcare’s network deploys AI across 120 sites, demonstrating how centralized IT can rapidly enhance diagnostic quality.

Primary-care clinics enhance triage capabilities through handheld ultrasound, thereby shortening referral loops and alleviating hospital bottlenecks. Mixed-model chains that pair imaging with pathology services also emerge, capturing synergies through cross-selling. The Australian diagnostic imaging equipment market, therefore, sees end-user segmentation widen, providing vendors multiple purchase channels.

Geography Analysis

Australia accounted for 84.30% of revenue in 2025, driven by a USD 69.8 million MRI licensing expansion and a USD 266.9 million nuclear medicine rebate pool, which together lifted scan volumes across urban and regional sites. Workforce gaps remain acute, with a deficit of 3,000 sonographers, resulting in scan wait times exceeding 30 days in some states. Supply-chain vulnerabilities include technetium-99m outages and the reliance on imported helium for legacy magnets; however, the fast adoption of helium-light platforms mitigates this risk.

The policy emphasis on timely imaging aligns with the Needs-Based Funding frameworks, which channel blended payments to providers who achieve service-level benchmarks. This integrated approach supports sustainable capital allocation and underpins a resilient long-term outlook for the Australian diagnostic imaging equipment market.

Regulatory Landscape

Diagnostic imaging equipment in Australia is regulated by the Therapeutic Goods Administration (TGA) as medical devices under the Therapeutic Goods Act 1989 and the Therapeutic Goods (Medical Devices) Regulations 2002. Suppliers generally need inclusion in the Australian Register of Therapeutic Goods (ARTG) before supply, backed by technical and clinical evidence demonstrating conformity with the Essential Principles for safety and performance (Schedule 1), with additional classification and clinical evaluation considerations for active diagnostic devices.

Commercialization for imported systems typically requires an Australian sponsor, such as a local subsidiary or distributor, to carry ARTG and post-market responsibilities, while importers must also meet compliance obligations across supply and distribution. Alongside TGA requirements for device and software-based medical devices, including AI-enabled functions assessed by intended purpose, procurement economics are influenced by Medicare settings tied to modality lifespans and practice licensing, which can accelerate replacement when equipment reaches defined age thresholds and compliance needs.

Value Chain Analysis

Australia relies heavily on multinational OEMs for CT, MRI, ultrasound, X-ray, nuclear imaging, fluoroscopy, and mammography systems, with in-country sponsors and specialist distributors supporting market access, installation, and lifecycle service. Firms such as ParagonCare, INLINE Systems, and InMed Healthcare commonly sit between manufacturers and end users, including hospitals, consolidated imaging chains, and independent practices, where they bundle procurement support with applications training, accessories, parts logistics, and multi-year service agreements designed to maintain uptime across widely dispersed sites.

In parallel, third-party logistics and service partners support warehousing, calibration, and field service dispatch, which can be particularly important for regional and remote operations and for managing movements of high-value, fragile capital equipment. Software is increasingly a distinct value-chain layer, since AI-enabled imaging tools and workflow platforms still need to fit within TGA medical-device requirements and ARTG inclusion pathways, pushing providers toward integrated IT deployment models covering scanners, PACS/RIS connectivity, cybersecurity, and ongoing software updates across vendor-neutral or multi-vendor environments.

Market Opportunities and Future Outlook

Public-sector capacity expansion and major hospital redevelopments are building active procurement pipelines for high-end CT and MRI, particularly beyond the largest metro cores. In May 2026, Queensland announced a Statewide MRI and CT Expansion Program allocating AUD 276 million for 11 new MRI and CT installations across regional Queensland. New South Wales also continued equipment refresh tied to major redevelopments, including advanced imaging technology delivered to Nepean Hospital as part of its Stage 2 redevelopment and a completed medical imaging upgrade at Wollongong Hospital (April 2026). These programs support opportunities for OEMs and integrators able to deliver turnkey rooms, align installation scheduling to construction timelines, and provide regional maintenance coverage.

Medicare mechanisms further support a structured replacement cycle for installed fleets through modality lifespans and related compliance settings, creating demand for upgrades that improve dose management, throughput, and energy use. At the same time, gaps in workforce capacity and rural access point to solutions such as AI-enabled workflow software and portable imaging configurations that reduce reliance on scarce specialist staff. Vendor financing and managed service models also help smaller facilities manage high upfront costs for advanced modalities.